Individualised cancer vaccine (Immunovative Therapies)

N/A

Report date: 2024/03/01 20:05:21

Base Information

Drug NameIndividualised cancer vaccine (Immunovative Therapies)
Drug Alias NameCRCL-AlloVaxAlloVax
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryThailandIsrael
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunovative Therapies Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmunovative Therapies Ltd
Active IndicationsN/A
Inactive IndicationsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A